A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

About

Brief Summary

The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.

Primary Purpose
The main objective of the intervention(s) being evaluated by the clinical trial. Learn more
Other
Study Type
The nature of the investigation or investigational use for which clinical study information is being submitted. Learn more
Interventional
Phase
Phase 3

Eligibility

Gender
Male
Healthy Volunteers
No
Minimum Age
N/A
Maximum Age
N/A

Inclusion Criteria:

  • Received delandistrogene moxeparvovec for Duchenne muscular dystrophy in a previous clinical study.
  • Has (a) parent(s) or legal caregiver(s) or is ≥18 years of age and able to understand and comply with the study visit schedule and all other protocol requirements.

Exclusion Criteria:

  • Not applicable

Join this Trial

Enrolling by Invitation
These studies are not open to everyone who meets the eligibility criteria, but only to people in that particular population, who are specifically invited to participate.
Study Stats
Protocol No.
23-000873
Category
Genetic and Rare Diseases
Musculoskeletal Disorders
Pediatric Disorders
Principal Investigator
Contact
  • Michael Yan
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05967351
For detailed technical eligibility, visit ClinicalTrials.gov.